|Bid||218.49 x 1100|
|Ask||218.53 x 1000|
|Day's Range||214.25 - 219.08|
|52 Week Range||176.11 - 256.22|
|Beta (3Y Monthly)||1.51|
|PE Ratio (TTM)||51.29|
|Earnings Date||May 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||247.25|
The latest earnings announcement IDEXX Laboratories, Inc. (NASDAQ:IDXX) released in December 2018 suggested that the company gained from a robust tailwind...
Idexx Laboratories Inc NASDAQ/NGS:IDXXView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for IDXX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding IDXX are favorable with net inflows of $98.54 billion. This was the highest net inflow seen over the last one-year.Error parsing the SmartText Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
WESTBROOK, Maine, April 2, 2019 /PRNewswire/ -- IDEXX Laboratories, Inc. (IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, has scheduled the release of its 2019 first quarter financial results for Wednesday, May 1, 2019 before the market opens. Individuals can access a live webcast of the conference call through a link on the IDEXX website, www.idexx.com/investors. To listen to the live conference call, please dial 1-800-230-1092 or 1-612-288-0337 and reference confirmation code 465882.
It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index […]
The innovation-based, multi-modality global strategy, enabled by enhanced commercial capability, accelerates IDEXX's (IDXX) recurring CAG Diagnostics revenue growth.
Continued weakness in the global animal protein market and strongly negative currency conversions posed as headwinds for Neogen (NEOG) in third-quarter fiscal 2019.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on a lighter note, a goo...
A diversified product portfolio and strong Dental business prospects provide Patterson Companies (PDCO) a competitive edge in the MedTech space.
Allscripts' (MDRX) partnership with Opargo is likely to improve scheduling capabilities and practice workflows of Allscripts Practice Management solution.
Strong international presence and an acquisition-driven strategy are likely to fortify Stryker's (SYK) footprint in the global MedTech space.
Pulse8 is likely to boost Allscripts' (MDRX) flagship platform Veradigm, and its existing health plan product suite that delivers pocket-friendly tools and services for health plan members.
McKesson (MCK) is well positioned for growth backed by strong business plans and robust surprise trend amid cutthroat competition in the near term.
Qatar-based Alfardan Group and Chicago-based Northwestern Medicine select Allscripts (MDRX) for the launch of a project in the Middle East.
Cooper Companies (COO) maintains its leading position in the markets of specialty lenses. Further, the company exits first-quarter fiscal 2019 on a strong note.
Expanding customer base of the NanoKnife platform is likely to fortify AngioDynamics' (ANGO) foothold in the Medical Instruments space.
WESTBROOK, Maine , March 4, 2019 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, today announced ...
Today we're going to take a look at the well-established IDEXX Laboratories, Inc. (NASDAQ:IDXX). The company's stock saw a decent share price growth in the teens level on the NASDAQGSRead More...
IDEXX Laboratories Inc develops, manufactures and distributes products and provide services for companion animal veterinary, livestock and poultry, dairy and water testing markets. IDEXX Laboratories Inc had annual average EBITDA growth of 13.10% over the past ten years. GuruFocus rated IDEXX Laboratories Inc the business predictability rank of 5-star.